Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT01927341 |
| Title | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NLD | ITA | FRA | ESP | CAN | BEL |